Sulfamerazin — Competitive Intelligence Brief

Sulfamerazin (SULFAMERAZINE) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: sulfamerazine. Area: Infectious Disease.

marketed sulfamerazine Dihydropteroate synthase Infectious Disease Small molecule

Target snapshot

Sulfamerazin (SULFAMERAZINE) — Pfizer. Sulfamerazine works by inhibiting the synthesis of folic acid in bacteria, which is essential for their growth and replication.

Comparator set (6 drugs)

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
Sulfamerazin TARGET	SULFAMERAZINE	Pfizer	marketed	sulfamerazine	Dihydropteroate synthase	1949-01-01
Sulfabid	SULFAPHENAZOLE	Purdue Frederick	marketed	sulfaphenazole	Cytochrome P450 2C9, Dihydropteroate synthase	1974-01-01
Aldapsone	aldesulfone	AbbVie	marketed	aldesulfone	Glucose-6-phosphate 1-dehydrogenase, Dihydropteroate synthase 1	1974-01-01
Gantrisin	SULFISOXAZOLE ACETYL	Roche	marketed		Endothelin B receptor, Endothelin-1 receptor, Dihydropteroate synthase	1953-01-01
Sulfamethazine	sulfadimidine	Pfizer	marketed	sulfadimidine	Lactoylglutathione lyase, Dihydropteroate synthase	1949-01-01
trimethoprim-sulfamethoxazole + metronidazole	trimethoprim-sulfamethoxazole + metronidazole	Halmstad County Hospital	marketed	Antibiotic combination	Bacterial dihydrofolate reductase, dihydropteroate synthase, and anaerobic DNA
Artesunate + Sulfadoxine-Pyrimethamine	Artesunate + Sulfadoxine-Pyrimethamine	Sanofi	marketed	Antimalarial combination	Plasmodium falciparum (multiple targets: artemisinin-induced oxidative stress; dihydrofolate reductase; dihydropteroate synthase)

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (sulfamerazine class)

1. Pfizer · 1 drug in this class